Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Badalona – page 256

3 651 clinical trials in Badalona, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Badalona at a glance
3 651
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

3 651 trials in Badalona

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Endocrine ophthalmopathy

Not recruiting

Study of Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Triple negative breast cancer

Not recruiting

Study of Capivasertib and Paclitaxel for Patients with Advanced or Metastatic Triple-Negative Breast Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Psoriasis

Not recruiting

Study Comparing Risankizumab and Deucravacitinib for Adults with Moderate Plaque Psoriasis Eligible for Systemic Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colorectal cancer

Not recruiting

Study of Pembrolizumab and Olaparib for Patients with Advanced Colorectal Cancer with DNA Repair Deficiency

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:Grupo Espanol Multidisciplinar En Cancer Digestivo

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Novartis Pharma AG

Neoplasm

Not recruiting

Study on CTL-002 and Nivolumab for Patients with Advanced-Stage, Relapsed/Refractory Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:CatalYm GmbH

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm

Not recruiting

Study on the Safety and Effects of [177Lu]-NeoB in Patients with Advanced Solid Tumors Overexpressing GRPR

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Neob
  • Sponsor:Advanced Accelerator Applications International S.A.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Long-term Safety and Effectiveness of Danicopan with Ravulizumab or Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Badalona

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for multiple types of cancer such as pancreatic, gastric, and lung cancer. Research emphasizes novel therapeutic approaches and combination treatments.

  • Mantle Cell Lymphoma Studies
  • Advanced NSCLC Treatments
  • Breast Cancer Therapies

Studies are evaluating targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Research focusing on inflammatory and autoimmune disorders, with particular emphasis on new therapeutic approaches for various conditions affecting different body systems.

  • Cutaneous Lupus Erythematosus
  • Plaque Psoriasis
  • Hidradenitis Suppurativa

Trials aim to evaluate novel treatments and improve disease management strategies.

03 Infectious Diseases

Comprehensive studies addressing viral infections and preventive measures, including vaccine development and therapeutic interventions for various infectious diseases.

  • COVID-19 Vaccines
  • HIV Treatment
  • RSV Prevention

Focus on developing effective treatments and preventive strategies for viral infections.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.